Indoco’s CRO Division Clears USFDA Inspection With Zero Observations

Drug firm Indoco Remedies on Friday said its clinical research organisation AnaCipher has successfully cleared the United States Food and Drug Administration (USFDA) inspection with zero observations.

The inspection by the US health regulator was held from October 14 to 18, 2019, Indoco Remedies said in a BSE filing.

AnaCipher conducts bio-equivalence and bio-availability studies at its facility in Hyderabad.

Shares of Indoco Remedies closed at Rs 153.30 per scrip on BSE, up 6.20 per cent from its previous close. – Business Standard

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.